Form 4: Nuvalent CTO Benjamin Lane Receives Equity Grant

Nuvalent, Inc. Chief Technical Operations Officer Benjamin Lane was granted 9,500 restricted stock units and 19,000 stock options.

Summary

• Benjamin Lane, Chief Technical Operations Officer at Nuvalent, Inc., received an equity compensation package on April 1, 2026.
• The grant includes 9,500 restricted stock units (RSUs) which vest in three equal annual installments starting April 1, 2026.
• The grant also includes 19,000 stock options with an exercise price of $105.64, vesting in equal monthly installments over four years.
• Following these transactions, the reporting person holds 50,368 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Equity grants align the interests of the Chief Technical Operations Officer with long-term shareholder value.
• Vesting schedules for both RSUs and options encourage long-term retention of key executive talent.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Future share price performance is required for the stock options to provide value to the executive.
• Continued service requirements for vesting create dependency on the executive's ongoing employment.

Future Outlook

The equity grants are subject to continued service requirements, with RSUs vesting annually over three years and options vesting monthly over four years.

Management Comments

• The filing notes that the RSUs represent the right to receive one share of Class A Common Stock upon vesting.

Industry Context

StockSavvy.ai notes that equity-based compensation remains the standard mechanism for incentivizing executive leadership in the high-growth biotechnology sector to ensure alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of a mix of RSUs and stock options is consistent with standard executive compensation practices in the pharmaceutical and biotech industries.
• Vesting periods of 3-4 years are standard for retaining senior leadership in mid-cap biotech firms.

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.
• Employees and management are incentivized through long-term equity participation.

Next Steps

• Vesting of RSUs in annual installments starting April 2027.
• Vesting of stock options in monthly installments over the next 48 months.

Key Dates

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Equity Compensation, Biotech